Why the study?
Does the R4496C RyR2 mutation predispose mice to ventricular tachycardia upon adrenergic stimulation, and do beta-blockers prevent these arrhythmias?
Does the R4496C RyR2 mutation predispose mice to ventricular tachycardia upon adrenergic stimulation, and do beta-blockers prevent these arrhythmias?
The R4496C RyR2 mutation predisposes murine hearts to ventricular tachycardia upon adrenergic stimulation, and beta-blockers appear ineffective in preventing these arrhythmias in this model.
No takes yet. Share an insight, caveat, or question.
RyR(R4496C) mutation confers adrenergic VT susceptibility in mice; leaves open beta-blocker efficacy in human CPVT.
Cerrone et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: